| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2019: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2018: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Outline of Final Research Achievements |
Treatment in the acute phase of cerebral infarction is roughly classified into revascularization therapy and neuroprotective therapy. In the former case, thrombolytic therapy or cerebrovascular therapy is performed during the hyperacute phase (within 8 hours after cerebral infarction), but the indication is limited. The development of treatments such as neuroprotective drugs is urgent. In this study, we performed a mouse cerebral infarction model to verify the neuroprotective effects of neurosecretory peptides induced during the acute phase of cerebral infarction and to analyze the pathology of long-term cerebral infarction from the acute to the chronic phase. Although no neuroprotective effect of the peptide was observed, long-term persistence of inflammatory findings after cerebral infarction (4 weeks) was confirmed, suggesting that inflammatory control after cerebral infarction may be important as a therapeutic target.
|
